PolyPid Ltd. PYPD
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS2.09
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D | $23.8M | $22.8M | $16.1M | $28.0M | $30.6M | $17.0M | $14.1M | $12.6M | — |
| SG&A | $7.2M | $4.3M | $5.5M | $8.0M | $9.6M | $7.7M | $3.6M | $5.3M | — |
| Operating income | -$33.0M | -$28.0M | -$22.9M | -$38.9M | -$43.1M | -$26.3M | -$18.6M | -$18.4M | — |
| Pre-tax income | -$34.2M | -$29.0M | -$23.8M | -$39.4M | -$42.6M | — | — | — | — |
| Income tax | $5.0K | $42.0K | $69.0K | $129.0K | — | — | — | — | — |
| Net income | -$34.2M | -$29.0M | -$23.9M | -$39.6M | -$42.6M | -$36.9M | -$6.9M | $5.9M | — |
| EPS, basic | 2.09 | 4.91 | 16.99 | 61.09 | 68.27 | 4.48 | 23.69 | -0.16 | — |
| EPS, diluted | 2.09 | 4.91 | 16.93 | 61.09 | 68.27 | 4.48 | 23.69 | 0.86 | — |
| Shares, diluted (wtd. avg.) | 16.4M | 5.9M | 1.4M | 647,556 | 624,051 | 9.6M | 562,451 | 613,358 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.4M | $15.6M | $5.3M | $9.1M | $10.5M | $4.9M | $4.5M | $7.8M | $4.1M |
| Total current assets | $15.2M | $16.6M | $6.1M | $14.2M | $34.8M | $47.2M | $27.4M | — | — |
| Property, plant and equipment | $5.1M | $6.1M | $7.6M | $9.2M | $8.8M | $5.9M | $6.1M | — | — |
| Total assets | $22.3M | $25.2M | $15.4M | $26.0M | $44.2M | $75.8M | $33.8M | — | — |
| Accounts payable | — | — | — | — | — | $1.9M | $998.0K | — | — |
| Short-term debt | $988.0K | $6.8M | $4.0M | $4.0M | — | — | — | — | — |
| Total current liabilities | $7.7M | $12.7M | $7.3M | $8.6M | $8.1M | $2.9M | $2.6M | — | — |
| Long-term debt | — | $634.0K | $6.4M | — | — | — | — | — | — |
| Retained earnings | -$301.5M | -$267.3M | -$238.3M | -$214.4M | -$174.9M | -$132.3M | -$93.3M | — | — |
| Total equity | $11.0M | $7.7M | -$2.1M | $5.8M | $36.0M | $72.8M | -$87.6M | -$81.7M | -$88.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.9M | -$22.0M | -$17.2M | -$34.3M | -$32.4M | -$21.6M | -$17.4M | -$16.7M | — |
| Depreciation and amortisation | $1.5M | $1.6M | $1.8M | $1.7M | $1.1M | $1.0M | $947.0K | $411.0K | — |
| Stock-based compensation | $4.9M | $2.8M | $3.4M | $4.3M | $4.8M | $4.6M | $976.0K | $995.0K | — |
| Capital expenditure | $210.0K | $76.0K | $196.0K | $1.8M | $2.7M | $781.0K | $879.0K | $3.1M | — |
| Investing cash flow | -$6.7M | -$330.0K | $3.8M | $16.6M | $36.9M | -$40.8M | -$23.6M | $11.0M | — |
| Financing cash flow | $25.4M | $32.4M | $10.0M | $16.4M | $1.0M | $62.8M | $37.7M | $9.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-020370.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Goodwill
- R&D
- Buybacks
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Goodwill | — | — | — | — | — | — | — | — | — |
| R&D | — | $12.6M | $14.1M | $17.0M | $30.6M | $28.0M | $16.1M | $22.8M | $23.8M |
| Buybacks | — | — | — | — | — | — | — | — | — |
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |